Phase II study of intravenous Doxil® in malignant pleural mesothelioma

Yun Oh, Roman Perez-Soler, Frank V. Fossella, Bonnie S. Glisson, Jonathan Kurie, Garrett L. Walsh, Mylene Truong, Dong M. Shin

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Twenty-four patients with pleural mesothelioma received 50 mg/m2 of Doxil® every four weeks. At follow-up, the disease had stabilized in 43% percent of patients and had progressed in 57%. No objective responses were observed. Estimated median survival of all patients was 37 weeks. Major toxicities were erythrodysesthesia of hands and feet and myelosuppression. No cardiac toxicity was observed. We concluded that Doxil® at this dosage and schedule is inactive against pleural mesothelioma.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalInvestigational New Drugs
Issue number3
StatePublished - 2000
Externally publishedYes


  • Doxil®
  • Mesothelioma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II study of intravenous Doxil® in malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this